Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
(Thomson Reuters ONE) -
Addex Therapeutics /
Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 30 April 2013 - Addex Therapeutics (SIX:ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development,
announced that Tim Dyer, Co-Founder and Chief Financial Officer, will transition
to an external consulting role on 1 June 2013 and no longer serve as CFO.
"On behalf of Addex, I would like to express my sincere thanks to Tim for his
significant and valuable contributions to Addex and wish him continued success,"
said Bharatt Chowrira, Addex' Chief Executive Officer, and added, "Tim is an
accomplished CFO with significant business acumen and has played a key role in
the founding and growth of Addex. Tim has agreed to provide short-term
consulting services to Addex to ensure a smooth transition of roles and
responsibilities, and we look forward to finalizing the terms of the consulting
arrangement shortly."
"On behalf of the Addex Board of Directors I, too, would like to add our
sincere thanks and appreciation for the excellent job Tim has done and his
loyalty and dedication to Addex over the past decade," said André J. Mueller,
Chairman of Addex. "We wish him continued success in his future endeavors.
Thanks to Tim agreeing to a short-term external consulting role, Addex is
assured of a seamless transition."
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a development stage company
focused on advancing innovative oral small molecules against rare diseases
utilizing its pioneering allosteric modulation-based drug discovery platform.
The Company's two lead products are being investigated in Phase 2 clinical
testing: dipraglurant (an mGlu5 negative allosteric modulator or NAM) is being
developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-
LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive allosteric
modulator or PAM) is being developed in collaboration with Janssen
Pharmaceuticals, Inc. to treat both schizophrenia and anxiety as seen in
patients suffering from major depressive disorder. Addex is also advancing
several preclinical programs including: GABA-BR positive allosteric modulator
(PAM) for Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with
multiple sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4
PAM for MS, Parkinson's disease, anxiety and other diseases. Allosteric
modulators are an emerging class of small molecule drugs which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The Company uses
its proprietary discovery platform to target receptors and other proteins that
are recognized as essential for the therapeutic modulation of important diseases
with unmet medical needs.
Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
PR(at)addextherapeutics.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the
appointment of a new CFO, the potential approval of its products by regulatory
authorities, or regarding potential future revenues from such products. Such
forward-looking statements reflect the current views of Addex Therapeutics
regarding future events, future economic performance or prospects, and, by their
very nature, involve inherent risks and uncertainties, both general and
specific, whether known or unknown, or any other factor that may materially
differ from the plans, objectives, expectations, estimates and intentions
expressed or implied in such forward-looking statements. Such may in particular
cause actual results with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR
or other therapeutic targets to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can
be no guarantee regarding the timing of the appointment of a new CFO or that
allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutics
targets will be approved for sale in any market or by any regulatory authority.
Nor can there be any guarantee that allosteric modulators of mGlu2, mGlu4,
mGlu5, GABA-BR or other therapeutic targets will achieve any particular levels
of revenue (if any) in the future. In particular, management's expectations
regarding allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other
therapeutic targets could be affected by, among other things, unexpected actions
by our partners, unexpected regulatory actions or delays or government
regulation generally; unexpected clinical trial results, including unexpected
new clinical data and unexpected additional analysis of existing clinical data;
competition in general; government, industry and general public pricing
pressures; or the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Therapeutics is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise, except as may be required by applicable
laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Therapeutics via Thomson Reuters ONE
[HUG#1698089]
Unternehmensinformation / Kurzprofil:
Datum: 30.04.2013 - 20:45 Uhr
Sprache: Deutsch
News-ID 254819
Anzahl Zeichen: 7312
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
